Effect of the Botanical Compound LCS101 on Chemotherapy-Induced Symptoms in Patients with Breast Cancer: A Case Series Report
Noah Samuels1*, Yair Maimon2* (*co-first author); and Rachel Y. Zisk-Rony3
1 Center for Integrative Complementary Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.
2 Refuot Medical Center, Tel Aviv, Israel.
3 Henrietta Szold Hadassah-Hebrew University School of Nursing, Faculty of Medicine and Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
The treatment of breast cancer invariably results in severe and often debilitating symptoms that can cause significant distress and severely impair daily function and quality-of-life (QOL). We treated a series of 20 female breast cancer patients with the botanical compound LCS101 as adjuvant to conventional chemotherapy. At the end of the treatment regimen, patients rated their symptoms. 70% reported that they had either no or mildly severe levels of fatigue; 60% none to mildly severe weakness; 85% none to mildly severe pain; 70% none to mildly severe nausea; and 80% none to mildly severe vomiting. Only 20% reported severe impairment of overall function, and only 40% severely impaired QOL. No toxic effects were attributed by patients to the LCS101 treatment, and 85% reported that they believed the botanical compound had helped reduce symptoms. The effects of LCS101 on clinical outcomes in breast cancer should be tested further using randomized controlled trials.
Integrative Medicine Insights 2013:8 1–8
Link with video abstract presentation: